Technical Analysis for ALKS - Alkermes plc

Grade Last Price % Change Price Change
grade D 24.28 5.15% 1.19
ALKS closed up 5.15 percent on Thursday, July 18, 2019, on 1.18 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Earnings due: Jul 25

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical ALKS trend table...

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
Stochastic Reached Overbought Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
50 DMA Resistance Bearish 5.15%
50 DMA Resistance Bearish 3.85%
NR7 Range Contraction 3.85%

Older signals for ALKS ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes. The company offers RISPERDAL CONSTA for schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia; AMPYRA/ FAMPYRA for the treatment of multiple sclerosis; BYDUREON for the treatment of type II diabetes; VIVITROL for alcohol and opioid dependence; TRICOR, LIPANTHYL, LIPIDIL, and SUPRALIP to lower cholesterol; ZANAFLEX for muscle spasticity; AVINZA for severe pain; EMEND for the treatment of nausea associated with chemotherapy and surgery; and FOCALIN XR and RITALIN LA for attention deficit and hyperactivity disorder. Its products also include MEGACE ES for the treatment of cachexia associated with AIDS; LUVOX CR for obsessive-compulsive disorder; RAPAMUNE for the prevention of renal transplant rejection; NAPRELAN for various mild to moderate pain indications; VERAPAMIL SR, VERELAN, VERELAN PM, VERAPAMIL PM, VERECAPS, UNIVER, and AFE Ditab CR for hypertension; and DILZEM SR, DILZEM XL, DILTELAN, ACALIX CD, DINISOR, TILAZEM CR, and CARDIZEM CD for hypertension and/or angina. In addition, it develops ALKS 9070, which is in phase 3 study for the treatment of schizophrenia; ALKS 37 that is under phase 2b study for the treatment of opioid-induced constipation; ALKS 33, which has completed phase 2 study for modulation of brain opioid receptors; ALKS 5461 that is under phase 2 study for the treatment of depressive disorder, as well as under phase 1b study for the treatment of cocaine dependence; and ZOHYDRO for pain relief. The company serves pharmaceutical wholesalers, specialty pharmacies, and specialty distributors directly through its sales force. It has collaboration with Janssen Pharmaceutica N.V. for the development of RISPERDAL CONSTA. The company was founded in 1987 and is headquartered in Dublin, Ireland.
Chemistry Biopharmaceutical Pain Surgery Chemotherapy Multiple Sclerosis Organic Chemistry Schizophrenia Hypertension Morphinans Neurochemistry Nausea Ii Diabetes Obsessive Compulsive Disorder AIDS Angina Depressive Disorder Opioid Antagonists Pharmaceutical Wholesalers Treatment Of Multiple Sclerosis Atypical Antipsychotics Opioid Induced Constipation Renal Transplant
Is ALKS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 46.98
52 Week Low 21.29
Average Volume 1,297,853
200-Day Moving Average 31.843
50-Day Moving Average 23.3322
20-Day Moving Average 22.707
10-Day Moving Average 23.042
Average True Range 0.8394
ADX 18.11
+DI 25.8084
-DI 17.297
Chandelier Exit (Long, 3 ATRs ) 21.9668
Chandelier Exit (Short, 3 ATRs ) 23.9182
Upper Bollinger Band 24.0017
Lower Bollinger Band 21.4123
Percent B (%b) 1.11
BandWidth 11.403532
MACD Line -0.0045
MACD Signal Line -0.2645
MACD Histogram 0.26
Fundamentals Value
Market Cap 3.73 Billion
Num Shares 154 Million
EPS -1.29
Price-to-Earnings (P/E) Ratio -18.82
Price-to-Sales 10.50
Price-to-Book 7.03
PEG Ratio -1145.21
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 26.46
Resistance 3 (R3) 26.29 25.39 26.10
Resistance 2 (R2) 25.39 24.83 25.47 25.98
Resistance 1 (R1) 24.83 24.49 25.11 25.01 25.86
Pivot Point 23.93 23.93 24.07 24.02 23.93
Support 1 (S1) 23.38 23.38 23.66 23.55 22.70
Support 2 (S2) 22.48 23.03 22.56 22.58
Support 3 (S3) 21.92 22.48 22.46
Support 4 (S4) 22.10